uniQure to Participate in Multiple Upcoming Industry Conferences in April
April 01 2021 - 7:05AM
uniQure to Participate in Multiple Upcoming Industry Conferences in
April
uniQure N.V. (NASDAQ: QURE), a leading gene therapy company
advancing transformative therapies for patients with severe medical
needs, today announced its participation in the following upcoming
virtual investor and scientific conferences:
- Virtual Guggenheim
Healthcare Talks│2021 Genomic
Medicines & Rare Disease, April 1, 2021
- Members of uniQure’s management
team will participate in virtual one-on-one investor meetings
throughout the day on Thursday, April 1.
- Matt Kapusta, chief executive
officer, will participate on a panel discussion entitled, “The
Low-Hanging Fruit in Gene Therapy Might Be Hard to Reach –
Challenges for Hemophilia A and B” on Thursday, April 1 from 10:00
to 10:50 a.m. ET. The live webcast of the fireside chat can be
accessed through the link displayed in the Investors & Newsroom
section of the uniQure website.
- Ricardo Dolmetsch, Ph.D., president
of research and development, will participate in a panel discussion
entitled, “An Idea Whose Time has Come – Disease Modifying
Therapies for Huntington’s Disease” later the same day from 3:00 to
3:50 p.m. ET.
- Wells Fargo Corporate
Access Days, April 6-8, 2021
- Members of uniQure’s management
team will participate in virtual one-on-one investor meetings
throughout the day on Tuesday, April 6.
- Professional Patient Advocates in Life Sciences, April
13, 2021
- Daniel Leonard, senior director of global patient advocacy,
will participate on a virtual panel discussion entitled, “Building
an Internal Patient Advocacy & HR Relationship Series – Part 1:
Journey to Patient Advocacy” starting at 2:00 p.m. ET on Tuesday,
April 13.
-
20th Annual Needham
Virtual Healthcare Conference, April 12 - 15, 2021
- Members of uniQure’s management
team will participate in virtual one-on-one investor meetings
throughout the day on Thursday, April 15.
- A company presentation with Matt
Kapusta will take place the same day from 3:45 to 4:25 p.m. ET. The
live webcast of the fireside chat can be accessed through the link
displayed in the Investors & Newsroom section of the uniQure
website.
- Chardan
5th Annual Genetic Medicines
Manufacturing Summit, April 26 - 27, 2021
- Members of uniQure’s management
team will participate in virtual one-on-one investor meetings on
Tuesday, April 27.
- A fireside chat with Matt Kapusta
will take place the same day from 1:45 to 2:25 p.m. ET. The live
webcast of the fireside chat can be accessed through the link
displayed in the Investors & Newsroom section of the uniQure
website.
- Kempen Life Sciences
Conference – 2021 Thematic Virtual Series “Cell, Gene & RNA
based companies,” April 28, 2021
- Members of uniQure’s management
team will participate in virtual one-on-one investor meetings on
Wednesday, April 28.
- CHDI’s 16th Annual
Huntington’s Disease Therapeutics Conference, April 27-29,
2021
- David Cooper, M.D., vice president of clinical research CNS,
will present in the clinical stage interventional programs session
on Thursday, April 29 between 10:00 a.m. and 12:30 p.m. ET. His
presentation is entitled, “Updates on HD-GeneTRX-1: A Phase 1-2
Clinical Trial of CNS-Administered Gene Therapy (AMT-130) for
Early-Stage HD.” Following the pre-recorded presentation, Dr.
Cooper will be available for live Q&A.
- Astrid Valles-Sanchez, Ph.D., senior scientist at uniQure, will
have a poster presentation entitled, “Lowering the Pathogenic Exon1
HTT Fragment by AAV5-miHTT Gene Therapy,” during the conference
dates.
- World Orphan Drug Congress, April 28, 2021
- Nick Li, Ph.D., M.B.A., senior director, global/US market
access lead, will participate on a panel entitled “Pricing &
Reimbursement for Rare Diseases in the United States” starting at
3:00 p.m. ET on Wednesday, April 28.
About uniQure uniQure is
delivering on the promise of gene therapy – single treatments with
potentially curative results. We are leveraging our modular and
validated technology platform to rapidly advance a pipeline of
proprietary gene therapies to treat patients with hemophilia B,
Huntington's disease, Fabry disease, spinocerebellar ataxia Type 3
and other diseases. www.uniQure.com
uniQure Contacts:
FOR
INVESTORS: |
|
FOR
MEDIA: |
|
|
|
Maria E. Cantor |
Chiara Russo |
Tom Malone |
Direct: 339-970-7536 |
Direct: 617-306-9137 |
Direct: 339-970-7558 |
m.cantor@uniQure.com |
c.russo@uniQure.com |
t.malone@uniQure.com |
Uniqure NV (TG:UQ1)
Historical Stock Chart
From Jun 2024 to Jul 2024
Uniqure NV (TG:UQ1)
Historical Stock Chart
From Jul 2023 to Jul 2024